Direct oral anticoagulants in cancer patients: which help from the specialist hemostasis and thrombosis laboratory?

Raimondo De Cristofaro, Leonardo Di Gennaro, Fabio Marazzi

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

Abstract

Oncologists continue to prefer traditional low molecular weight heparins over direct oral anticoagulants (DOAC) for the treatment of venous thromboembolism (VTE) cancer-related. Recently published studies supporting the use DOACs in this patient setting confirm the safety and efficacy of the treatment, but this still does not seem to be enough. The major obstacles to their use are interaction with chemotherapeutic agents, fear of haemorrhage, poor habit of using DOACs for VTE prophylaxis. But what if the haemostasis and thrombosis laboratory reassured oncologists? In this short report we talk about this topic in order to stimulate a fruitful discussion between expert.
Lingua originaleEnglish
pagine (da-a)130-131
Numero di pagine2
RivistaMedical Oncology
Volume38
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Administration, Oral
  • Anticoagulants
  • Venous Thromboembolism
  • Laboratories
  • Neoplasms
  • Humans

Fingerprint

Entra nei temi di ricerca di 'Direct oral anticoagulants in cancer patients: which help from the specialist hemostasis and thrombosis laboratory?'. Insieme formano una fingerprint unica.

Cita questo